These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 17260090

  • 1. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
    Arriola E, Rodriguez-Pinilla SM, Lambros MB, Jones RL, James M, Savage K, Smith IE, Dowsett M, Reis-Filho JS.
    Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials.
    Fountzilas G, Dafni U, Bobos M, Kotoula V, Batistatou A, Xanthakis I, Papadimitriou C, Kostopoulos I, Koletsa T, Tsolaki E, Televantou D, Timotheadou E, Koutras A, Klouvas G, Samantas E, Pisanidis N, Karanikiotis C, Sfakianaki I, Pavlidis N, Gogas H, Linardou H, Kalogeras KT, Pectasides D, Dimopoulos MA.
    BMC Cancer; 2013 Mar 28; 13():163. PubMed ID: 23537287
    [Abstract] [Full Text] [Related]

  • 3. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
    Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, Villalobos IE, Eiermann W, Pienkowski T, Martin M, Robert N, Crown J, Bee V, Taupin H, Flom KJ, Tabah-Fisch I, Pauletti G, Lindsay MA, Riva A, Slamon DJ.
    J Clin Oncol; 2011 Mar 01; 29(7):859-67. PubMed ID: 21189395
    [Abstract] [Full Text] [Related]

  • 4. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
    Fountzilas G, Valavanis C, Kotoula V, Eleftheraki AG, Kalogeras KT, Tzaida O, Batistatou A, Kronenwett R, Wirtz RM, Bobos M, Timotheadou E, Soupos N, Pentheroudakis G, Gogas H, Vlachodimitropoulos D, Polychronidou G, Aravantinos G, Koutras A, Christodoulou C, Pectasides D, Arapantoni P.
    J Transl Med; 2012 Jan 12; 10():10. PubMed ID: 22240029
    [Abstract] [Full Text] [Related]

  • 5. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
    Scandinavian Breast Group Trial 9401Laboratory of Cancer Biology, Institute of Medical Technology, and Department of Oncology, Tampere University and Tampere University Hospital, Tampere, Finland., Tanner M, Isola J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, Malmström P, Wilking N, Nilsson J, Bergh J.
    J Clin Oncol; 2006 Jun 01; 24(16):2428-36. PubMed ID: 16682728
    [Abstract] [Full Text] [Related]

  • 6. Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
    Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ.
    Br J Cancer; 2006 Nov 20; 95(10):1334-41. PubMed ID: 17088909
    [Abstract] [Full Text] [Related]

  • 7. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
    O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Bramwell VH, Andrulis IL, Pritchard KI.
    J Natl Cancer Inst; 2009 May 06; 101(9):644-50. PubMed ID: 19401546
    [Abstract] [Full Text] [Related]

  • 8. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
    Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H, Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L, Cameron D, Piccart MJ, Buyse M, HER2/TOP2A Meta-analysis Study Group.
    Lancet Oncol; 2011 Nov 06; 12(12):1134-42. PubMed ID: 21917518
    [Abstract] [Full Text] [Related]

  • 9. Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Fountzilas G, Christodoulou C, Bobos M, Kotoula V, Eleftheraki AG, Xanthakis I, Batistatou A, Pentheroudakis G, Xiros N, Papaspirou I, Koumarianou A, Papakostas P, Bafaloukos D, Skarlos DV, Kalogeras KT.
    J Transl Med; 2012 Oct 23; 10():212. PubMed ID: 23092535
    [Abstract] [Full Text] [Related]

  • 10. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A, Sükösd F, Kaizer L, Csörgo E, Vörös A, Uhercsák G, Ormándi K, Lázár G, Thurzó L, Brodowicz T, Kahán Z.
    Oncology; 2011 Oct 23; 80(3-4):269-77. PubMed ID: 21734419
    [Abstract] [Full Text] [Related]

  • 11. Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status.
    Tubbs R, Barlow WE, Budd GT, Swain E, Porter P, Gown A, Yeh IT, Sledge G, Shapiro C, Ingle J, Haskell C, Albain KS, Livingston R, Hayes DF.
    J Clin Oncol; 2009 Aug 20; 27(24):3881-6. PubMed ID: 19620488
    [Abstract] [Full Text] [Related]

  • 12. Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Tibau A, López-Vilaró L, Pérez-Olabarria M, Vázquez T, Pons C, Gich I, Alonso C, Ojeda B, Ramón y Cajal T, Lerma E, Barnadas A, Escuin D.
    Neoplasia; 2014 Oct 20; 16(10):861-7. PubMed ID: 25379022
    [Abstract] [Full Text] [Related]

  • 13. Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.
    García-Caballero T, Prieto O, Vázquez-Boquete A, Gude F, Viaño P, Otero M, Curiel T, Fernández-Rodríguez B, Parrado C, Fraga M, Antúnez JR.
    Breast Cancer Res Treat; 2014 Jan 20; 143(1):81-9. PubMed ID: 24292870
    [Abstract] [Full Text] [Related]

  • 14. TOP2A gene copy number change in breast cancer.
    Engstrøm MJ, Ytterhus B, Vatten LJ, Opdahl S, Bofin AM.
    J Clin Pathol; 2014 May 20; 67(5):420-5. PubMed ID: 24403186
    [Abstract] [Full Text] [Related]

  • 15. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer.
    Schindlbeck C, Mayr D, Olivier C, Rack B, Engelstaedter V, Jueckstock J, Jenderek C, Andergassen U, Jeschke U, Friese K.
    J Cancer Res Clin Oncol; 2010 Jul 20; 136(7):1029-37. PubMed ID: 20052594
    [Abstract] [Full Text] [Related]

  • 16. Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.
    Won HS, Lee KE, Sung SH, Choi MY, Jo JY, Nam EM, Mun YC, Seong CM, Lee SN.
    Tumori; 2014 Jul 20; 100(1):80-6. PubMed ID: 24675496
    [Abstract] [Full Text] [Related]

  • 17. Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
    Varga Z, Moelans CB, Zuerrer-Hardi U, Ramach C, Behnke S, Kristiansen G, Moch H.
    Breast Cancer Res Treat; 2012 Jun 20; 133(3):929-35. PubMed ID: 22083232
    [Abstract] [Full Text] [Related]

  • 18. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
    Bartlett JM, Munro AF, Dunn JA, McConkey C, Jordan S, Twelves CJ, Cameron DA, Thomas J, Campbell FM, Rea DW, Provenzano E, Caldas C, Pharoah P, Hiller L, Earl H, Poole CJ.
    Lancet Oncol; 2010 Mar 20; 11(3):266-74. PubMed ID: 20079691
    [Abstract] [Full Text] [Related]

  • 19. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines.
    Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, Jones C, Dowsett M, Ashworth A, Reis-Filho JS.
    Lab Invest; 2008 May 20; 88(5):491-503. PubMed ID: 18332872
    [Abstract] [Full Text] [Related]

  • 20. Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.
    Nielsen KV, Ejlertsen B, Møller S, Jensen MB, Balslev E, Müller S, Knoop A, Mouridsen HT.
    Mol Oncol; 2012 Feb 20; 6(1):88-97. PubMed ID: 22153616
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.